Charles River Laboratories (CRL)

Financial leverage ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Total assets	US$ in thousands	7,528,340	8,003,840	7,948,280	8,152,780	8,195,000	7,607,010	7,772,380	7,699,440	7,602,770	7,382,770	7,529,360	7,075,050	7,024,290	7,058,440	6,720,350	5,808,960	5,490,830	5,213,340	5,240,880	5,201,790
Total stockholders’ equity	US$ in thousands	3,461,500	3,782,270	3,722,730	3,640,440	3,596,880	3,305,990	3,251,700	3,108,600	2,976,290	2,626,850	2,647,710	2,610,180	2,534,820	2,426,570	2,318,440	2,183,930	2,114,600	1,896,940	1,752,640	1,651,980
Financial leverage ratio		2.17	2.12	2.14	2.24	2.28	2.30	2.39	2.48	2.55	2.81	2.84	2.71	2.77	2.91	2.90	2.66	2.60	2.75	2.99	3.15

December 31, 2024 calculation

Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $7,528,340K ÷ $3,461,500K
= 2.17

The financial leverage ratio of Charles River Laboratories has displayed a declining trend over the last few years, decreasing from 3.15 as of March 31, 2020, to 2.17 as of December 31, 2024. This reduction suggests that the company has been gradually decreasing its reliance on debt to finance its operations and growth. A lower financial leverage ratio indicates a lower level of financial risk and greater solvency for the company, as it implies that a smaller portion of the company's assets is funded by debt. Charles River Laboratories' declining financial leverage ratio may indicate a conservative financial strategy focused on maintaining a strong balance sheet and financial stability.